Plain-English translation of NCT05689034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people with COVID-19 who have health conditions that put them at higher risk of getting very sick. About half of the participants will receive the medication along with standard care, and the other half will receive a placebo (a pill with no medicine) along with standard care. Researchers will compare how the two groups do over time.
Right now, there are not many treatment options for people with early COVID-19 who are at higher risk of severe illness. This trial wants to find out if this medication can help prevent these high-risk patients from progressing to severe COVID-19.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to either receive the medication or placebo. You will take 5 tablets by mouth every day for up to 7 days, along with your regular medical care (but not other antiviral medications). The study team will monitor you during this time to see how you respond and whether you develop severe illness.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China